Literature DB >> 7591304

Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung.

I Sugawara1, H Yamada, H Nakamura, T Sumizawa, S Akiyama, A Masunaga, S Itoyama.   

Abstract

The expression of multidrug-resistance-associated protein (MRP) was assessed in various types of untreated lung cancer using an immunohistochemical technique. MRP was abundantly expressed in 28 of 59 adenocarcinoma specimens (47%) and its expression was associated with the degree of glandular differentiation of the tumor. MRP expression in well-differentiated adenocarcinomas (56%) was higher than in poorly differentiated adenocarcinomas (22%) (p < 0.01). lower--20% in squamous-cell carcinomas, 20% in large-cell carcinomas and 0% in small-cell carcinomas and carcinoids. RT-PCR showed that the MRP-positive adenocarcinomas and squamous-cell carcinomas expressed mrp mRNA significantly. Immunoelectron microscopically, MRP was localized in the plasma membrane and rough endoplasmic reticulum. It is thus important to take MRP into account when considering chemotherapy for lung cancers because levels of mdr I gene product, another multidrug-resistance gene family, are low in untreated lung cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591304     DOI: 10.1002/ijc.2910640507

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.

Authors:  Qi Wang; Jun Qian; Junyu Wang; Chun Luo; Juxiang Chen; Guohan Hu; Yicheng Lu
Journal:  J Neurooncol       Date:  2013-01-06       Impact factor: 4.130

Review 2.  Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).

Authors:  Eva Bakos; László Homolya
Journal:  Pflugers Arch       Date:  2006-12-23       Impact factor: 3.657

3.  Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.

Authors:  Walter Berger; Ulrike Setinek; Peter Hollaus; Thomas Zidek; Elisabeth Steiner; L Elbling; H Cantonati; Johannes Attems; Andrea Gsur; Michael Micksche
Journal:  J Cancer Res Clin Oncol       Date:  2005-01-27       Impact factor: 4.553

4.  Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.

Authors:  Janet Wangari-Talbot; Elizabeth Hopper-Borge
Journal:  J Can Res Updates       Date:  2013-10-31

5.  Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.

Authors:  J Kreisholt; M Sorensen; P B Jensen; B S Nielsen; C B Andersen; M Sehested
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.